Literature DB >> 32267478

With First CRISPR Trials, Gene Editing Moves Toward the Clinic.

Tracy Hampton.   

Abstract

Year:  2020        PMID： 32267478     DOI： 10.1001/jama.2020.3438

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

Review 1.  One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.

Authors:  Marjolein M Ensinck; Marianne S Carlon
Journal:  Cells       Date:  2022-06-08       Impact factor: 7.666

2.  Inadequate reporting quality of registered genome editing trials: an observational study.

Authors:  Diana Jurić; Michael Zlatin; Ana Marušić
Journal:  BMC Med Res Methodol       Date:  2022-05-02       Impact factor: 4.612

Review 3.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

4.  Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models.

Authors:  Sandeep R P Kumar; Dennis O Pérez-López; Chady H Hakim; Nalinda B Wasala; Dong Zhang; Yongping Yue; James Teixeira; Xiufang Pan; Keqing Zhang; Emily D Million; Christopher E Nelson; Samantha Metzger; Jin Han; Jacqueline A Louderman; Florian Schmidt; Feng Feng; Dirk Grimm; Bruce F Smith; Gang Yao; N Nora Yang; Charles A Gersbach; Shi-Jie Chen; Roland W Herzog; Dongsheng Duan
Journal:  Nat Commun       Date:  2021-11-24       Impact factor: 17.694
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.